Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
Status:
Completed
Trial end date:
2021-02-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of LCZ696 at a target dose of 200 mg b.i.d.
compared to enalapril 10 mg b.i.d., in addition to the background heart failure (HF)
treatment, on delaying time to first occurrence of either cardiovascular (CV) death or HF
hospitalization events in Japanese patients with stable chronic heart failure (CHF), New York
Heart Association (NYHA) classes II-IV and reduced ejection fraction (left ventricular
ejection fraction (LVEF) ≤ 35%).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Enalapril Enalaprilat LCZ 696 Sacubitril and valsartan sodium hydrate drug combination